GuruFocus.com8d agobearish
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent CliffMorgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
75last 24h
977last 7d
110● bullish (7d)
126● bearish (7d)
212publishers
The Wall Street Journal23d agobearish
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth ConcernsThe stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.
Investing.com45d agobearish
Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlookInvesting.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.